Biocom is hosting a briefing on the merits of pre-clinical virtual drug development by Explora Biolabs and MPI Research. Explora BioLabs will discuss selecting a drug candidate using early biology/efficacy models as well as best practices for screening and partnering with a CRO to streamline your candidate selection in a resource constrained environment. Building on that discussion, MPI Research will describe how to advance a compound from early GLP toxicology and safety testing into phase 1 while utilizing successful partnerships. More information and online registration is here.